Jubilant Pharmova soars as its arm launches New Sterile Fill & Finish line at facility in US
Jubilant Pharmova is currently trading at Rs. 1121.65, up by 25.95 points or 2.37% from its previous closing of Rs. 1095.70 on the BSE.
The scrip opened at Rs. 1099.15 and has touched a high and low of Rs. 1134.00 and Rs. 1093.00 respectively. So far 6005 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1309.00 on 07-Nov-2024 and a 52 week low of Rs. 823.70 on 09-Apr-2025.
Last one week high and low of the scrip stood at Rs. 1136.90 and Rs. 1081.00 respectively. The current market cap of the company is Rs. 17880.10 crore.
The promoters holding in the company stood at 47.68%, while Institutions and Non-Institutions held 26.92% and 25.40% respectively.
Jubilant Pharmova’s wholly owned subsidiary -- Jubilant HollisterStier LLC (JHS) has launched its New Sterile Fill & Finish line, third at its Spokane Manufacturing Facility in Washington, US. The launch was marked by the successful production of the inaugural batch, initiating revenue generation from the new Line. The launch plays a key role in Jubilant HollisterStier’s multi-phase expansion strategy and brings an additional 50% capacity at its Spokane manufacturing facility. JHS is a leading North American pharmaceutical contract manufacturer, specialising in sterile injectables and serves top global innovator pharma companies.
Together with the commissioning of its upcoming Fourth Line, JHS is on track to double its total sterile injectable manufacturing capacity at its Spokane facility in the US. This strategic investment further reinforces JHS’ leadership in domestic US pharmaceutical manufacturing. By expanding its infrastructure and increasing onshore capacity, the company is contributing to US national health security and helping to reduce reliance on offshore supply chains - delivering a more resilient and agile pharmaceutical manufacturing ecosystem.
Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses
